These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
338 related articles for article (PubMed ID: 25308528)
81. New insights into immune mechanisms of vitiligo. Boniface K; Taïeb A; Seneschal J G Ital Dermatol Venereol; 2016 Feb; 151(1):44-54. PubMed ID: 26512930 [TBL] [Abstract][Full Text] [Related]
82. Clinical Features, Immunopathogenesis, and Therapeutic Strategies in Vitiligo. Wang Y; Li S; Li C Clin Rev Allergy Immunol; 2021 Dec; 61(3):299-323. PubMed ID: 34283349 [TBL] [Abstract][Full Text] [Related]
83. Polymeric nanoparticles containing rapamycin and autoantigen induce antigen-specific immunological tolerance for preventing vitiligo in mice. Zhang X; Liu D; He M; Lin M; Tu C; Zhang B Hum Vaccin Immunother; 2021 Jul; 17(7):1923-1929. PubMed ID: 33616474 [TBL] [Abstract][Full Text] [Related]
84. Self-tolerance and autoimmunity in a regulatory T cell model. Alexander HK; Wahl LM Bull Math Biol; 2011 Jan; 73(1):33-71. PubMed ID: 20195912 [TBL] [Abstract][Full Text] [Related]
85. Vitiligo: what's new in the psycho-neuro-endocrine-immune connection and related treatments. Lotti T; Zanardelli M; D'Erme AM Wien Med Wochenschr; 2014 Jul; 164(13-14):278-85. PubMed ID: 25059737 [TBL] [Abstract][Full Text] [Related]
91. A central role for inducible heat-shock protein 70 in autoimmune vitiligo. Mosenson JA; Eby JM; Hernandez C; Le Poole IC Exp Dermatol; 2013 Sep; 22(9):566-9. PubMed ID: 23786523 [TBL] [Abstract][Full Text] [Related]
92. Advances in the treatment options for vitiligo: activated low-dose cytokines-based therapy. Lotti T; Hercogova J; Fabrizi G Expert Opin Pharmacother; 2015; 16(16):2485-96. PubMed ID: 26372794 [TBL] [Abstract][Full Text] [Related]
93. Vitiligo--Part 2--classification, histopathology and treatment. Faria AR; Tarlé RG; Dellatorre G; Mira MT; Castro CC An Bras Dermatol; 2014; 89(5):784-90. PubMed ID: 25184918 [TBL] [Abstract][Full Text] [Related]
94. The role of IL-17 in vitiligo: A review. Singh RK; Lee KM; Vujkovic-Cvijin I; Ucmak D; Farahnik B; Abrouk M; Nakamura M; Zhu TH; Bhutani T; Wei M; Liao W Autoimmun Rev; 2016 Apr; 15(4):397-404. PubMed ID: 26804758 [TBL] [Abstract][Full Text] [Related]
95. Melanocyte destruction and repopulation in vitiligo. Norris DA; Horikawa T; Morelli JG Pigment Cell Res; 1994 Aug; 7(4):193-203. PubMed ID: 7855062 [No Abstract] [Full Text] [Related]
96. Vitiligo: a review of the published work. Yaghoobi R; Omidian M; Bagherani N J Dermatol; 2011 May; 38(5):419-31. PubMed ID: 21667529 [TBL] [Abstract][Full Text] [Related]
99. Clinical features and course of type A and type B vitiligo. Koga M; Tango T Br J Dermatol; 1988 Feb; 118(2):223-8. PubMed ID: 3348967 [TBL] [Abstract][Full Text] [Related]